Angiogenesis, the generation of new blood vessels, is an essential physiological process that can be dysregulated in various pathological conditions, including cancer. The vascular endothelial growth factor (VEGF) pathway is considered the most important and is a well-characterized contributor to angiogenesis. VEGF-A and other members of the VEGF family such as placental growth factor (PlGF) are upregulated in pathological conditions. VEGF-A, the first VEGF characterized, has served as a paradigm for the development of antiangiogenesis as a therapeutic strategy.
The global VEGF Targeted Drugs market size is projected to grow from US$ 891 million in 2024 to US$ 1303 million in 2030; it is expected to grow at a CAGR of 6.5% from 2024 to 2030.
The 鈥淰EGF Targeted Drugs Industry Forecast鈥 looks at past sales and reviews total world VEGF Targeted Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected VEGF Targeted Drugs sales for 2023 through 2029. With VEGF Targeted Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world VEGF Targeted Drugs industry.
This Insight Report provides a comprehensive analysis of the global VEGF Targeted Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on VEGF Targeted Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥 unique position in an accelerating global VEGF Targeted Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for VEGF Targeted Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global VEGF Targeted Drugs.
United States market for VEGF Targeted Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for VEGF Targeted Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for VEGF Targeted Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key VEGF Targeted Drugs players cover Roche, Eli Lilly, Pfizer, Regeneron Pharmaceuticals, Novartis, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of VEGF Targeted Drugs market by product type, application, key players and key regions and countries.
Segmentation by Type:
Bevacizumab
Ramucirumab
Ranibizumab
Aflibercept
Conbercept
Other
Segmentation by Application:
Hospitals
Clinics
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
Bevacizumab
Ramucirumab
Ranibizumab
Aflibercept
Conbercept
Other
Segmentation by Application:
Hospitals
Clinics
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Eli Lilly
Pfizer
Regeneron Pharmaceuticals
Novartis
Alphamab Oncology
Chengdu Kanghong Pharmaceutical
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global VEGF Targeted Drugs 麻豆原创 Size 2019-2030
2.1.2 VEGF Targeted Drugs 麻豆原创 Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for VEGF Targeted Drugs by Country/Region, 2019, 2023 & 2030
2.2 VEGF Targeted Drugs Segment by Type
2.2.1 Bevacizumab
2.2.2 Ramucirumab
2.2.3 Ranibizumab
2.2.4 Aflibercept
2.2.5 Conbercept
2.2.6 Other
2.3 VEGF Targeted Drugs 麻豆原创 Size by Type
2.3.1 VEGF Targeted Drugs 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global VEGF Targeted Drugs 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 VEGF Targeted Drugs Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.5 VEGF Targeted Drugs 麻豆原创 Size by Application
2.5.1 VEGF Targeted Drugs 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global VEGF Targeted Drugs 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 VEGF Targeted Drugs 麻豆原创 Size by Player
3.1 VEGF Targeted Drugs 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global VEGF Targeted Drugs Revenue by Player (2019-2024)
3.1.2 Global VEGF Targeted Drugs Revenue 麻豆原创 Share by Player (2019-2024)
3.2 Global VEGF Targeted Drugs Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 VEGF Targeted Drugs by Region
4.1 VEGF Targeted Drugs 麻豆原创 Size by Region (2019-2024)
4.2 Global VEGF Targeted Drugs Annual Revenue by Country/Region (2019-2024)
4.3 Americas VEGF Targeted Drugs 麻豆原创 Size Growth (2019-2024)
4.4 APAC VEGF Targeted Drugs 麻豆原创 Size Growth (2019-2024)
4.5 Europe VEGF Targeted Drugs 麻豆原创 Size Growth (2019-2024)
4.6 Middle East & Africa VEGF Targeted Drugs 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas VEGF Targeted Drugs 麻豆原创 Size by Country (2019-2024)
5.2 Americas VEGF Targeted Drugs 麻豆原创 Size by Type (2019-2024)
5.3 Americas VEGF Targeted Drugs 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC VEGF Targeted Drugs 麻豆原创 Size by Region (2019-2024)
6.2 APAC VEGF Targeted Drugs 麻豆原创 Size by Type (2019-2024)
6.3 APAC VEGF Targeted Drugs 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe VEGF Targeted Drugs 麻豆原创 Size by Country (2019-2024)
7.2 Europe VEGF Targeted Drugs 麻豆原创 Size by Type (2019-2024)
7.3 Europe VEGF Targeted Drugs 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa VEGF Targeted Drugs by Region (2019-2024)
8.2 Middle East & Africa VEGF Targeted Drugs 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa VEGF Targeted Drugs 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global VEGF Targeted Drugs 麻豆原创 Forecast
10.1 Global VEGF Targeted Drugs Forecast by Region (2025-2030)
10.1.1 Global VEGF Targeted Drugs Forecast by Region (2025-2030)
10.1.2 Americas VEGF Targeted Drugs Forecast
10.1.3 APAC VEGF Targeted Drugs Forecast
10.1.4 Europe VEGF Targeted Drugs Forecast
10.1.5 Middle East & Africa VEGF Targeted Drugs Forecast
10.2 Americas VEGF Targeted Drugs Forecast by Country (2025-2030)
10.2.1 United States 麻豆原创 VEGF Targeted Drugs Forecast
10.2.2 Canada 麻豆原创 VEGF Targeted Drugs Forecast
10.2.3 Mexico 麻豆原创 VEGF Targeted Drugs Forecast
10.2.4 Brazil 麻豆原创 VEGF Targeted Drugs Forecast
10.3 APAC VEGF Targeted Drugs Forecast by Region (2025-2030)
10.3.1 China VEGF Targeted Drugs 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 VEGF Targeted Drugs Forecast
10.3.3 Korea 麻豆原创 VEGF Targeted Drugs Forecast
10.3.4 Southeast Asia 麻豆原创 VEGF Targeted Drugs Forecast
10.3.5 India 麻豆原创 VEGF Targeted Drugs Forecast
10.3.6 Australia 麻豆原创 VEGF Targeted Drugs Forecast
10.4 Europe VEGF Targeted Drugs Forecast by Country (2025-2030)
10.4.1 Germany 麻豆原创 VEGF Targeted Drugs Forecast
10.4.2 France 麻豆原创 VEGF Targeted Drugs Forecast
10.4.3 UK 麻豆原创 VEGF Targeted Drugs Forecast
10.4.4 Italy 麻豆原创 VEGF Targeted Drugs Forecast
10.4.5 Russia 麻豆原创 VEGF Targeted Drugs Forecast
10.5 Middle East & Africa VEGF Targeted Drugs Forecast by Region (2025-2030)
10.5.1 Egypt 麻豆原创 VEGF Targeted Drugs Forecast
10.5.2 South Africa 麻豆原创 VEGF Targeted Drugs Forecast
10.5.3 Israel 麻豆原创 VEGF Targeted Drugs Forecast
10.5.4 Turkey 麻豆原创 VEGF Targeted Drugs Forecast
10.6 Global VEGF Targeted Drugs Forecast by Type (2025-2030)
10.7 Global VEGF Targeted Drugs Forecast by Application (2025-2030)
10.7.1 GCC Countries 麻豆原创 VEGF Targeted Drugs Forecast
11 Key Players Analysis
11.1 Roche
11.1.1 Roche Company Information
11.1.2 Roche VEGF Targeted Drugs Product Offered
11.1.3 Roche VEGF Targeted Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Roche Main Business Overview
11.1.5 Roche Latest Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Company Information
11.2.2 Eli Lilly VEGF Targeted Drugs Product Offered
11.2.3 Eli Lilly VEGF Targeted Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Eli Lilly Main Business Overview
11.2.5 Eli Lilly Latest Developments
11.3 Pfizer
11.3.1 Pfizer Company Information
11.3.2 Pfizer VEGF Targeted Drugs Product Offered
11.3.3 Pfizer VEGF Targeted Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Pfizer Main Business Overview
11.3.5 Pfizer Latest Developments
11.4 Regeneron Pharmaceuticals
11.4.1 Regeneron Pharmaceuticals Company Information
11.4.2 Regeneron Pharmaceuticals VEGF Targeted Drugs Product Offered
11.4.3 Regeneron Pharmaceuticals VEGF Targeted Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Regeneron Pharmaceuticals Main Business Overview
11.4.5 Regeneron Pharmaceuticals Latest Developments
11.5 Novartis
11.5.1 Novartis Company Information
11.5.2 Novartis VEGF Targeted Drugs Product Offered
11.5.3 Novartis VEGF Targeted Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Novartis Main Business Overview
11.5.5 Novartis Latest Developments
11.6 Alphamab Oncology
11.6.1 Alphamab Oncology Company Information
11.6.2 Alphamab Oncology VEGF Targeted Drugs Product Offered
11.6.3 Alphamab Oncology VEGF Targeted Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Alphamab Oncology Main Business Overview
11.6.5 Alphamab Oncology Latest Developments
11.7 Chengdu Kanghong Pharmaceutical
11.7.1 Chengdu Kanghong Pharmaceutical Company Information
11.7.2 Chengdu Kanghong Pharmaceutical VEGF Targeted Drugs Product Offered
11.7.3 Chengdu Kanghong Pharmaceutical VEGF Targeted Drugs Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 Chengdu Kanghong Pharmaceutical Main Business Overview
11.7.5 Chengdu Kanghong Pharmaceutical Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.